Welcome to our dedicated page for Panbela Therapeutics news (Ticker: PBLA), a resource for investors and traders seeking the latest updates and insights on Panbela Therapeutics stock.
Panbela Therapeutics Inc. (PBLA) is a clinical-stage biopharmaceutical company pioneering therapies targeting polyamine metabolism in aggressive cancers. This page serves as the definitive source for verified news and press releases related to clinical trials, research breakthroughs, and corporate developments.
Investors and researchers will find timely updates on PBLA's oncology pipeline, including ivospemin (SBP-101) and combination therapies under investigation. Our curated collection provides essential context for understanding the company's progress in pancreatic, ovarian, and other solid tumor research.
Key content categories include clinical trial milestones, regulatory updates, peer-reviewed data publications, and strategic partnership announcements. All materials are sourced directly from the company and reputable medical journals to ensure accuracy.
Bookmark this page for streamlined access to PBLA's latest developments in cancer therapeutics. For comprehensive analysis of how these updates may impact therapeutic landscapes and investment considerations, consult your financial advisor or medical professional.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announced a conference call scheduled for March 24, 2022, at 4:30 PM ET to discuss its fourth-quarter results for the period ending December 31, 2021. The call will focus on the performance and outlook for SBP-101, its lead product for treating metastatic pancreatic cancer, which has shown a median overall survival of 12 months and an objective response rate of 48% in clinical studies. Investors can participate via toll-free or international numbers, or through an online webcast.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) announces that an abstract for SBP-101, a proprietary polyamine analogue, will be presented at the American Association for Cancer Research (AACR) meeting from April 8-13, 2022. This research highlights a collaboration with Johns Hopkins University. SBP-101 aims to inhibit polyamine metabolism, showing promising results in clinical studies for metastatic pancreatic cancer, including a median overall survival of 12 months and an objective response rate of 48%. The safety profile indicates no exacerbation of common chemotherapy-related side effects.
Panbela Therapeutics (Nasdaq: PBLA) announced an agreement to acquire Cancer Prevention Pharmaceuticals to diversify its pipeline, targeting a $5 billion market for cancer therapies. The combined pipeline spans pre-clinical to registration studies, expected to generate significant catalysts. A fully funded registration trial for the lead asset will initiate by year-end. Post-merger, Panbela stockholders will hold approximately 59% of the company, while CPP stakeholders will own 41%. The deal aims to maximize shareholder value through operational synergies and enhanced patient treatment capabilities.
Panbela Therapeutics (Nasdaq: PBLA) has announced the launch of its global Phase 2 clinical trial, named the ASPIRE trial, for SBP-101 in combination with Gemcitabine and Nab-Paclitaxel to treat metastatic pancreatic ductal adenocarcinoma. The trial has begun at Summit Cancer Centers with plans to activate around 60 additional sites in 2022. The study is a randomized, double-blind, placebo-controlled trial focused on overall survival, with a completion target of patient enrollment within 12 months. SBP-101 has shown potential in previous studies without exacerbating common chemotherapy-related adverse effects.
Panbela Therapeutics (Nasdaq: PBLA) reported interim results from its Phase 1b study of SBP-101 in combination with gemcitabine and nab-paclitaxel for metastatic pancreatic ductal adenocarcinoma. The interim data revealed a median overall survival of 12.0 months and an objective response rate of 48%, both exceeding historical rates. Despite dose interruptions affecting results, cohort 2 showed an impressive 71% response rate. The safety profile indicated manageable Grade ≥3 adverse events. Panbela plans to advance to a Phase 2 randomized trial and explore additional indications.
Panbela Therapeutics (Nasdaq: PBLA) announced promising preclinical results for SBP-101 in ovarian cancer cell lines, highlighting its potential in a field of significant unmet medical need. The company aims to initiate a development program for SBP-101 in ovarian cancer in H1 2022 and will conduct a virtual R&D day to provide further insights. With ovarian cancer being a major cause of cancer deaths among women, the focus on SBP-101 underscores the importance of addressing this critical health issue.
Panbela Therapeutics (Nasdaq: PBLA) announced the acceptance of an abstract for a poster presentation of SBP-101 at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The presentation will focus on the efficacy of SBP-101, a polyamine metabolic inhibitor, in combination with gemcitabine and nab-paclitaxel for first-line treatment of metastatic pancreatic ductal adenocarcinoma. The safety profile shows no exacerbation of common chemotherapy-related adverse events. Further evaluation in a randomized clinical trial is planned.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) reported positive clinical progress and financial results for Q3 2021. The company highlighted that 16 patients are in survival follow-up, with two exceeding 28 months. A patent notification was issued for a new production method for SBP-101, reducing synthesis steps significantly. Financially, the company recorded a net loss of $2.1 million, or $0.16 per share, and reported cash and equivalents of $14.1 million. Management aims to initiate randomized trials and expand indications by year-end.
Panbela Therapeutics, Inc. (Nasdaq: PBLA) will host a conference call on November 10, 2021, at 4:30 PM ET to discuss its third-quarter results for the period ending September 30, 2021. Participants can join via a toll-free number or online. The company is developing SBP-101, a treatment targeting metastatic pancreatic cancer, with promising clinical signals of efficacy. Safety data from trials indicate that SBP-101 does not exacerbate chemotherapy-related adverse effects, which supports further clinical evaluation.
Panbela Therapeutics (Nasdaq: PBLA) announced participation in two upcoming investor conferences:
- H.C. Wainwright 23rd Annual Global Investment Conference: September 13-15, 2021. Presentation available on-demand from September 13.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23, 2021, with a presentation on September 21 at 9:55am ET.
Management will host 1x1 investor meetings at both events. Panbela is focused on developing SBP-101, a treatment for pancreatic cancer.
